157 related articles for article (PubMed ID: 36503370)
1. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.
Marchese PV; Mollica V; Tassinari E; De Biase D; Giunchi F; Marchetti A; Rosellini M; Fiorentino M; Massari F
Expert Rev Mol Diagn; 2022 Nov; 22(11):997-1008. PubMed ID: 36503370
[TBL] [Abstract][Full Text] [Related]
2. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
Günes C; Wezel F; Southgate J; Bolenz C
Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
[TBL] [Abstract][Full Text] [Related]
3. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
5. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
Cheng L; Zhang S; Wang M; Lopez-Beltran A
Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749
[TBL] [Abstract][Full Text] [Related]
6. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
[TBL] [Abstract][Full Text] [Related]
8. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
9.
Liu T; Li S; Xia C; Xu D
Front Immunol; 2022; 13():1071390. PubMed ID: 36713366
[TBL] [Abstract][Full Text] [Related]
10. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
[TBL] [Abstract][Full Text] [Related]
13. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
15. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
18. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
Marchese PV; Mollica V; De Biase D; Giunchi F; Tassinari E; Marchetti A; Rosellini M; Nuvola G; Maloberti T; Fiorentino M; Massari F
Pathol Res Pract; 2022 Aug; 236():153983. PubMed ID: 35751929
[TBL] [Abstract][Full Text] [Related]
19.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
20. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.
Wan S; Liu X; Hua W; Xi M; Zhou Y; Wan Y
Bioengineered; 2021 Dec; 12(1):1495-1504. PubMed ID: 33938397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
